Guggenheim started coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $32.00 price target on the stock.
Separately, Morgan Stanley began coverage on shares of Alumis in a research report on Tuesday. They set an overweight rating and a $36.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $27.50.
Alumis Stock Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Alumis stock. Towerview LLC acquired a new position in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 310,000 shares of the company’s stock, valued at approximately $4,123,000. Alumis accounts for about 2.7% of Towerview LLC’s holdings, making the stock its 8th biggest holding. Towerview LLC owned 0.66% of Alumis as of its most recent filing with the Securities & Exchange Commission.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
- Five stocks we like better than Alumis
- How to Find Undervalued Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Effectively Use the MarketBeat Ratings Screener
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are Growth Stocks and Investing in Them
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.